Fig. 1 · Structure
Documents & Downloads
Pinatuzumab vedotin
ADC
Pinatuzumab vedotin is an antibody-drug conjugate (ADC) that targets CD22 through a humanized monoclonal antibody, Pinatuzumab, linked to the cytotoxic agent VcMMAE. This compound exhibits significant antitumor activity, making it valuable for research in targeted cancer therapies. Its application primarily includes investigations into CD22-expressing malignancies and the development of novel therapeutic strategies in oncology.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1313706-14-7 |
| Applications | ADC |
| Synonyms | anti-CD22-vc-MMAE; DCDT2980S |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.